Journal of Hepatology最新文献

{"title":"From the Editor’s Desk...","authors":"Philip Newsome, Frank Tacke, Heiner Wedemeyer, Lorenza Rimassa, Annalisa Berzigotti, Tom H. Karlsen, Vlad Ratziu","doi":"10.1016/j.jhep.2025.02.040","DOIUrl":"10.1016/j.jhep.2025.02.040","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 5","pages":"Pages 773-776"},"PeriodicalIF":26.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward functional cure of hepatitis B: Is combination therapy the key?","authors":"Lisa Sandmann","doi":"10.1016/j.jhep.2025.03.024","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.03.024","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Chronic hepatitis B virus (HBV) infection is a major health burden and it is estimated that 3% of the world’s population are chronically infected.¹ Infected individuals are at risk of developing chronic liver disease leading to cirrhosis, liver-related complications and development of hepatocellular carcinoma (HCC).² Antiviral treatment with nucleos(t)ide analogues (NA) effectively suppresses HBV DNA replication thereby reducing the risk of disease progression and HCC development in patients</section></section><section><section><h2>Objectives, methods and findings</h2>In the phase II study published in the <em>New England Journal of Medicine</em>, 160 patients with chronic HBV infection and established effective NA treatment without clinically significant fibrosis or cirrhosis were randomly assigned to receive (A) xalnesiran 100 mg or (B) 200 mg, (C) xalnesiran 200 mg plus ruzotolimod 150 mg, (D) xalnesiran 200 mg plus pegylated interferon alfa (PEG-IFN), all in addition to continued NA treatment, or (E) NA alone.⁹ The total treatment duration was 48 weeks in all</section></section><section><section><h2>Significance of findings</h2>This study demonstrated that combination treatment with a small-interfering RNA (xalnesiran) and an immune-modulatory agent (ruzotolimod or PEG-IFN) in addition to continued NA treatment led to HBsAg loss in a substantial proportion of patients. Interestingly, response rates were higher in patients receiving PEG-IFN compared to the TLR7 agonist ruzotolimod. The reasons for these differences are unclear but could be due to the broader immunomodulatory activity of IFN, which affects both the</section></section><section><section><h2>Financial support</h2>The authors did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Conflict of interest</h2>The author of this study declares that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"183 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EASL Guidelines app is your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Download it now!","authors":"","doi":"10.1016/S0168-8278(25)00179-5","DOIUrl":"10.1016/S0168-8278(25)00179-5","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 5","pages":"Page iii"},"PeriodicalIF":26.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Join the community and become an EASL member today!","authors":"","doi":"10.1016/S0168-8278(25)00180-1","DOIUrl":"10.1016/S0168-8278(25)00180-1","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 5","pages":"Page iv"},"PeriodicalIF":26.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes","authors":"Juan Vaz, Patrik Nasr, Anders Helander, Ying Shang, Axel Wester, Rickard Strandberg, Emilie Toresson Grip, Hannes Hagström","doi":"10.1016/j.jhep.2025.04.019","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.019","url":null,"abstract":"&lt;h3&gt;Background &amp; Aims&lt;/h3&gt;Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion of patients with or at risk for metabolic dysfunction-associated steatotic liver disease (MASLD) who had PEth levels indicative of harmful alcohol consumption, and to assess associations between PEth levels and the risk of major adverse liver outcomes (MALOs).&lt;h3&gt;Methods&lt;/h3&gt;We conducted a cohort study involving persons tested for PEth in Stockholm, Sweden between 2012 and 2020 (N=46,406), including patients with various steatotic liver disease (SLD) subtypes and individuals without SLD. Cumulative incidences of MALOs were calculated for the different groups while accounting for competing risk. Cox regression was used to evaluate the association between baseline PEth levels and the incidence of MALOs.&lt;h3&gt;Results&lt;/h3&gt;Among 6,377 patients with presumed MASLD, 1,294 (20%) had baseline PEth levels between 0.05 and 0.30 μmol/L (35-210 ng/ml), indicating excessive alcohol intake (MetALD), while 854 patients (13%) had values &gt;0.30 μmol/L, indicating alcohol-related liver disease (ALD). Patients with MASLD and PEth levels between 0.05-0.30 μmol/L had similar median FIB-4 scores and cirrhosis prevalence as those with MASLD and PEth levels &lt;0.05 μmol/L. However, patients with PEth levels between 0.05-0.30 μmol/L had higher cumulative incidences of MALOs compared to those with PEth levels &lt;0.05 μmol/L. Elevated PEth levels were significantly linked to higher rates of MALOs in patients without cirrhosis, even after adjustments for age, sex, SLD subtype, and FIB-4 score. Patients with ALD had the highest PEth levels and worst prognosis.&lt;h3&gt;Conclusions&lt;/h3&gt;PEth is a valuable alcohol biomarker for distinguishing between SLD subtypes, especially ALD, and predicts adverse outcomes in people with and without SLD.&lt;h3&gt;Impact and implications&lt;/h3&gt;There is controversy regarding the various proposed steatotic liver disease (SLD) subtypes, the most recent definition suggesting that patients with an elevated alcohol consumption and MASLD should be classified as having MetALD. Here, we address this challenge by classifying patients with SLD by utilizing the biomarker phosphatidylethanol (PEth), a direct and reliable biomarker for recent alcohol consumption. Our analysis of this large cohort—comprising 46,406 patients—revealed that using the objective PEth biomarker may be a valuable tool for distinguishing between MASLD and MetALD, and that PEth is strongly associated with the risk of liver outcomes in individuals with and without known SLD.Integrating PEth testing into routine diagnostic evaluations could enhance knowledge on the underlying pathophysiology in SLD, reduce the potential for misclassification, and ultimately improve patient outcomes by enabling clinicians to offer appropriate therapies. Further research is needed to validate these findings in other populations and to expl","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"37 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease","authors":"Marta Tonon, Roberta Gagliardi, Enrico Pompili, Anna Barone, Giacomo Zaccherini, Gianluca Zilio, Maurizio Baldassarre, Antonio Accetta, Daniele Carrello, Valeria Calvino, Giulia Iannone, Simone Incicco, Nicola Zeni, Carmine Gabriele Gambino, Paolo Caraceni, Paolo Angeli, Salvatore Piano","doi":"10.1016/j.jhep.2025.04.018","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.018","url":null,"abstract":"<h3>Background and Aims</h3>Baveno-VII consensus recently defined recompensation in patients with decompensated cirrhosis achieving etiological cure. However, incidence, predictors and clinical significance of recompensation are poorly known. This study aimed to evaluate the incidence and prognostic impact of recompensation in patients with decompensated cirrhosis.<h3>Methods</h3>Outpatients with cirrhosis and curable etiologies (alcohol, HCV, HBV) were consecutively included and followed up. Recompensation was defined according to Baveno VII criteria. Additionally, expanded recompensation criteria were evaluated for patients on low dose diuretics and/or lactulose/rifaximin for ≥12 months. In 160 patients, inflammatory cytokines (IL-6,IL-1β, IL-10) were measured in serum samples. An external cohort was used to validate study findings.<h3>Results</h3>298 out of 525 decompensated cirrhotic outpatients achieved an effective etiological treatment and 21 (7%) achieved recompensation (Baveno-VII criteria), while 112 patients achieved expanded recompensation criteria (37.6%). MELD score (sHR=0.89; p&lt;0.001), BMI (sHR=0.93; p=0.020), hemoglobin (sHR=1.14; p=0.010) and further decompensation (sHR=0.50; p=0.001) were independent predictors of recompensation. In multivariable analysis, mortality risk was not significantly different between patients achieving recompensation and compensated patients (HR=0.97; p=0.947), while decompensated patients had the highest mortality risk (HR=4.96; p&lt;0.001). Mortality risk was not significantly different between patients meeting expanded recompensation criteria and Baveno-VII criteria (HR=0.97; p=0.938). Serum IL-6, IL-1beta and IL-10 were significantly higher in decompensated patients than in compensated and recompensated patients.<h3>Conclusion</h3>Baveno-VII criteria identify cirrhotic patients with a good prognosis, but fewer than 10% of decompensated patients achieve recompensation. Expanding these criteria to include patients receiving minimal decompensation treatment identifies those with similarly low mortality risk.<h3>Impact and implications</h3>In recent years, growing evidence has shown that achieving an etiological cure can significantly improve the prognosis of decompensated patients, leading to the development of the concept of recompensation. Baveno VII recently proposed a definition for recompensation; however, data on the clinical impact of this condition remain limited. In this study we evaluated Baveno VII criteria and developed and validated expanded Baveno VII criteria for recompensation. Our findings demonstrates that recompensation is associated with improved survival, reduced hyperdynamic circulation and decreased systemic inflammation in outpatients with decompensated cirrhosis. These results are valuable for hepatologists and researchers aiming to refine patient management strategies and risk stratification in cirrhosis care.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"21 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Analysis of Statistical Methods in Albumin Treatment Study: Advocating for Nonlinear Approaches in Biological Data Analysis","authors":"Yoshiyasu Takefuji","doi":"10.1016/j.jhep.2025.04.009","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.009","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Yoshiyasu Takefuji completed this research and wrote this article.</section></section><section><section><h2>Financial support</h2>This research has no fund.</section></section><section><section><h2>Declaration of Competing Interest</h2>The author has no conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"39 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.","authors":"Flavia Ferreira Fernandes, Paula Guedes Ferreira da Silva, Cristiane Alves Villela Nogueira","doi":"10.1016/j.jhep.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.010","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Data availability statement (delete if not applicable)</h2>Data can be made available upon reasonable request.</section></section><section><section><h2>Uncited reference</h2>7.; 7..</section></section><section><section><h2>Authors' contributions</h2>Study concept and design: Fernandes F, Villela-Nogueira C.Acquisition of data: all authors.Analysis and interpretation of data: Fernandes F, Villela-Nogueira C.Drafting of the manuscript: Fernandes F, Villela-Nogueira C.Critical revision of the manuscript for important intellectual content: all authorsStatistical analysis: Villela-Nogueira C.</section></section><section><section><h2>Financial support</h2>Nothing to declare.</section></section><section><section><h2>Declaration of Competing Interest</h2>Nothing to declare.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"108 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aberrant ubiquitination causing liver cancer: the ADRM1-ΔEx9- FBXW7 connection","authors":"Diego F. Calvisi","doi":"10.1016/j.jhep.2025.03.032","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.03.032","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Conflict of interest</h2>Nothing to discloseHepatocellular carcinoma (HCC), accounting for approximately 85%-90% of primary liver tumors, is the sixth most common malignancy and the third cause of cancer- related mortality worldwide. Surgical resection, liver transplantation, and locoregional therapies can potentially cure early-stage HCC. However, the prognosis for patients with advanced HCC is still poor. Indeed, despite the introduction of different, systemic therapies, such as immune checkpoint inhibitors and</section></section><section><section><h2>Financial support</h2>None</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"23 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply on the need for an adult-to-adult liver graft split policy","authors":"Christian Toso, Julie Heimbach, Constantino Fondevila","doi":"10.1016/j.jhep.2025.04.007","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.007","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>All authors contributed to the design and writing.</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Declaration of Competing Interest</h2>None</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"4 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}